Search

Your search keyword '"Malaguti, Paola"' showing total 27 results
Start Over Author "Malaguti, Paola"
27 results on '"Malaguti, Paola"'

1. p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study

Author

Fabi, Alessandra, Mottolese, Marcella, Di Benedetto, Anna, Sperati, Francesca, Ercolani, Cristiana, Buglioni, Simonetta, Nisticò, Cecilia, Ferretti, Gianluigi, Vici, Patrizia, Perracchio, Letizia, Malaguti, Paola, Russillo, Michelangelo, Botti, Claudio, Pescarmona, Edoardo, Cognetti, Francesco, and Terrenato, Irene

Published
2020
Full Text
View/download PDF

2. MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study

Author

Turinetto, Margherita, primary, Ricotti, Andrea, additional, Marchetti, Claudia, additional, Pisano, Carmela, additional, Zamagni, Claudio, additional, Cassani, Chiara, additional, Malaguti, Paola, additional, Baldoni, Alessandra, additional, Scollo, Paolo, additional, Scandurra, Giuseppa, additional, Parisi, Alessandro, additional, Artioli, Grazia, additional, Palaia, Innocenza, additional, Vertechy, Laura, additional, Bergamini, Alice, additional, Picardo, Elisa, additional, Tuninetti, Valentina, additional, Scotto, Giulia, additional, Scambia, Giovanni, additional, Pignata, Sandro, additional, and Valabrega, Giorgio, additional

Published
2023
Full Text
View/download PDF

3. T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer

Author

Fabi, Alessandra, Alesini, Daniele, Valle, Enrichetta, Moscetti, Luca, Caputo, Roberta, Caruso, Michele, Carbognin, Luisa, Ciccarese, Mariangela, La Verde, Nicla, Arpino, Grazia, Cannita, Katia, Paris, Ida, Santini, Daniele, Montemurro, Filippo, Russillo, Michelangelo, Ferretti, Gianluigi, Filippelli, Gianfranco, Rossello, Rosalba, Fabbri, Agnese, Zambelli, Alberto, Leonardi, Vita, D’Ottavio, Anna Maria, Nisticò, Cecilia, Stani, Simonetta, Giampaglia, Marianna, Scandurra, Giusy, Catania, Giovanna, Malaguti, Paola, Giannarelli, Diana, and Cognetti, Francesco

Published
2018
Full Text
View/download PDF

4. MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study

Author

Turinetto, Margherita, Ricotti, Andrea, Marchetti, Claudia, Pisano, Carmela, Zamagni, Claudio, Cassani, Chiara, Malaguti, Paola, Baldoni, Alessandra, Scollo, Paolo, Scandurra, Giuseppa, Parisi, Alessandro, Artioli, Grazia, Palaia, Innocenza, Vertechy, Laura, Bergamini, Alice, Picardo, Elisa, Tuninetti, Valentina, Scotto, Giulia, Scambia, Giovanni, and Pignata, Sandro

Subjects
THERAPEUTIC use of antineoplastic agents, DRUG efficacy, RESEARCH, DISEASE progression, HAND-foot syndrome, OVARIAN tumors, SCIENTIFIC observation, CONFIDENCE intervals, DOXORUBICIN, RESEARCH methodology, CASE-control method, RETROSPECTIVE studies, GASTROINTESTINAL diseases, PLATINUM, BLOOD diseases, DESCRIPTIVE statistics, RESEARCH funding, FATIGUE (Physiology), ENZYME inhibitors, EVALUATION
Abstract

Simple Summary: This multicenter, retrospective analysis had the objective of comparing the efficacy of PLD-Trabectedin in patients who had already been treated with PARP-I (cases) before vs. PARPi-naïve patients (controls). Data from 166 patients were collected, composed of 109 cases and 57 controls. In total, 135 patients were included in our analyses, composing 46 controls and 89 cases. We found a median PFS of 11 months (95% IC 10–12) in the control group vs. 8 months (95% IC 6–9) in the case group (p value 0.0017). The clinical benefit rate was evaluated, with an HR for progression of 2.55 (1.28–5.06) for the case group (p value 0.008) persisting when adjusted for BRCA mutation. The study showed a statistically significant difference in terms of PFS, suggesting that a previous exposure to PARP-i might inhibit the efficacy of PLD-Trabectedin. Regarding tolerability, no remarkable disparity was noted. Objective: While PLD-Trabectedin is an approved treatment for relapsed platinum-sensitive ovarian cancer, its efficacy and tolerability has so far not been tested extensively in patients who progress after poly ADP-ribose polymerase inhibitor (PARPi) treatment. Methodology: This multicenter, retrospective analysis had the objective of comparing patients receiving PLD-Trabectedin after being treated with PARP-I (cases) with PARPi-naïve patients. Descriptive and survival analyses were performed for each group. Results: Data from 166 patients were collected, composed of 109 cases and 57 controls. In total, 135 patients were included in our analyses, composing 46 controls and 89 cases. The median PFS was 11 months (95% IC 10–12) in the control group vs. 8 months (95% IC 6–9) in the case group (p value 0.0017). The clinical benefit rate was evaluated, with an HR for progression of 2.55 (1.28–5.06) for the case group (p value 0.008), persisting when adjusted for BRCA and line with treatment. We compared hematological toxicity, gastro-intestinal toxicity, hand–foot syndrome (HFS), fatigue, and liver toxicity, and no statistically significant disparity was noted, except for HFS with a p value of 0.006. The distribution of G3 and G4 toxicities was also equally represented. Conclusion: The MITO39 study showed a statistically significant difference in terms of PFS, suggesting that previous exposure to PARPi might inhibit the efficacy of PLD-Trabectedin. Regarding tolerability, no remarkable disparity was noted; PLD-Trabectedin was confirmed to be a well-tolerated scheme in both groups. To our knowledge, these are the first data regarding this topic, which we deem to be of great relevance in the current landscape. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Abstract OT1-16-01: Trial In Progress: An Evaluation of FACIT-Fatigue in Patients with Locally Advanced or Metastatic Breast Cancer receiving Treatment with Taxane-based Chemotherapy

Author

Fabi, Alessandra, primary, Hager, Steven, additional, Lourdes, Laura, additional, Pedersini, Rebecca, additional, Malaguti, Paola, additional, Gavioli, Elizabeth M., additional, Wakade, Renuka, additional, Ruffini, Pier Adelchi, additional, Sergio, Francesco, additional, Leone, Manuela, additional, Mantelli, Flavio, additional, Allegretti, Marcello, additional, and Blaes, Anne, additional

Published
2023
Full Text
View/download PDF

6. The immersive experience of virtual reality during chemotherapy in patients with early breast and ovarian cancers: The patient’s dream study

Author

Fabi, Alessandra, primary, Fotia, Luana, additional, Giuseppini, Federico, additional, Gaeta, Arianna, additional, Falcicchio, Chiara, additional, Giuliani, Gabriele, additional, Savarese, Antonella, additional, Taraborelli, Emanuela, additional, Rossi, Valentina, additional, Malaguti, Paola, additional, Giannarelli, Diana, additional, Pugliese, Patrizia, additional, and Cognetti, Francesco, additional

Published
2022
Full Text
View/download PDF

8. Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients

Author

Fabi, Alessandra, primary, Ferretti, Gianluigi, additional, Malaguti, Paola, additional, Gasparro, Simona, additional, Nisticò, Cecilia, additional, Arpino, Grazia, additional, Papaldo, Paola, additional, Russillo, Michelangelo, additional, Catania, Giovanna, additional, Schettini, Francesco, additional, Giannarelli, Diana, additional, and Cognetti, Francesco, additional

Published
2020
Full Text
View/download PDF

15. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients

Author

Fabi,Alessandra, Giannarelli,Diana, Malaguti,Paola, Ferretti,Gianluigi, Vari,Sabrina, Papaldo,Paola, Nisticò,Cecilia, Caterino,Mauro, De Vita,Roy, Mottolese,Marcella, Iacorossi,Laura, Cognetti,Francesco, Fabi,Alessandra, Giannarelli,Diana, Malaguti,Paola, Ferretti,Gianluigi, Vari,Sabrina, Papaldo,Paola, Nisticò,Cecilia, Caterino,Mauro, De Vita,Roy, Mottolese,Marcella, Iacorossi,Laura, and Cognetti,Francesco

Abstract

Alessandra Fabi,1 Diana Giannarelli,2 Paola Malaguti,1 Gianluigi Ferretti,1 Sabrina Vari,1 Paola Papaldo,1 Cecilia Nisticò,1 Mauro Caterino,3 Roy De Vita,4 Marcella Mottolese,5 Laura Iacorossi,6 Francesco Cognetti1 1Department of Medical Oncology, 2Biostatistic Unit, 3Service of Radiology, 4Operative Unit of Plastic and Reconstructive Surgery, Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy; 5Department of Pathology, 6Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy Background: There is a deep need to improve the care of metastatic breast cancer (MBC) patients, since even today it remains an incurable disease. Taxanes are considered the most effective cytotoxic drugs for the treatment of MBC, both in monotherapy and in combined schedules, but the need for synthetic solvents contributes to the severe toxicities and may have a negative impact on the efficacy. Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) is a colloidal suspension of paclitaxel and human serum albumin initially developed to avoid the toxicities associated with conventional taxanes.Patients and methods: The aim of this prospective, single-center open-label, noncomparative study was to evaluate the efficacy and safety of nab-paclitaxel in MBC patients pretreated with taxanes. The patients were treated with nab-paclitaxel as a single agent, 260 mg/m2 on day 1 of each 3-week cycle or 125 mg/m2 weekly. The primary endpoint was the overall response rate (ORR). Secondary objectives were duration of response, clinical benefit rate, progression-free survival (PFS), overall survival, and safety.Results: A total of 42 patients (median age 48 years, median Eastern Cooperative Oncology Group performance status 0, triple-negative MBC 19%, all pretreated with a taxane-based therapy, mainly in advanced disease) were enrolled in the study. The ORR was 23.8%, including one complete respo

Published
2015

16. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients

Author

Fabi, Alessandra, primary, Giannarelli, Diana, additional, Malaguti, Paola, additional, Ferretti, Gianluigi, additional, Vari, Sabrina, additional, Papaldo, Paola, additional, Nisticò, Cecilia, additional, Caterino, Mauro, additional, De Vita, Roy, additional, Mottolese, Marcella, additional, Cognetti, Francesco, additional, and Iacorossi, Laura, additional

Published
2015
Full Text
View/download PDF

17. [Pharmacogenomics and chemotherapy]

Author

Paris, Ida, Cappellini, Gian Carlo Antonini, Malaguti, Paola, Bassanelli, Maria, and Marchetti, Paolo

Subjects
Antimetabolites, Antineoplastic, Time Factors, Genotype, Antimetabolites, Drug Resistance, Antineoplastic Agents, Irinotecan, Toxicology, Genetic, Phytogenic, Neoplasms, Animals, Polymorphism, Enzyme Inhibitors, Dihydrouracil Dehydrogenase (NADP), Polymorphism, Genetic, Thymidylate Synthase, Antineoplastic, Antineoplastic Agents, Phytogenic, Survival Analysis, Drug Resistance, Neoplasm, Pharmacogenetics, Neoplasm, Camptothecin, Taxoids, Cisplatin, Fluorouracil
Abstract

Genetic factors could alter drug metabolism and activity and could predict drug toxicity and/or efficacy. Several chemotherapy agents are administered in different schedules for the treatment of different cancer histotypes. The most used drug in the treatment of gastro-intestinal, head and neck and breast neoplasms is the 5-fluorouracil (5-FU). Capecitabine is a prodrug of 5-FU. Cisplatin based chemotherapy is administered in the treatment of lung, genitourinary tract, head and neck, occult neoplasms, mesothelioma and melanoma. Taxanes are used in lung, breast, head and neck, genitourinary tract neoplasms and sarcomas. Determination of polymorphisms in metabolizing enzymes before the administration of chemotherapy could offer new strategies for optimizing the treatment of individual patients.

Published
2010

18. Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study

Author

Ferrandina, Maria Gabriella, Corrado, Giacomo, Mascilini, Floriana, Malaguti, Paola, Samaritani, Roberto, Distefano, Maria Grazia, Masciullo, Valeria, Di Legge, A, Savarese, Antonella, Scambia, Giovanni, Ferrandina, Maria Gabriella (ORCID:0000-0003-4672-4197), Scambia, Giovanni (ORCID:0000-0003-2758-1063), Ferrandina, Maria Gabriella, Corrado, Giacomo, Mascilini, Floriana, Malaguti, Paola, Samaritani, Roberto, Distefano, Maria Grazia, Masciullo, Valeria, Di Legge, A, Savarese, Antonella, Scambia, Giovanni, Ferrandina, Maria Gabriella (ORCID:0000-0003-4672-4197), and Scambia, Giovanni (ORCID:0000-0003-2758-1063)

Abstract

The aim of this multicenter, retrospective study was to evaluate the efficacy and safety of metronomic oral cyclophosphamide (MOC) in heavily treated, relapsed ovarian cancer (ROC) patients.

Published
2014

19. Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study

Author

Ferrandina, Gabriella, primary, Corrado, Giacomo, additional, Mascilini, Floriana, additional, Malaguti, Paola, additional, Samaritani, Riccardo, additional, Distefano, Mariagrazia, additional, Masciullo, Valeria, additional, Di Legge, Alessia, additional, Savarese, Antonella, additional, and Scambia, Giovanni, additional

Published
2014
Full Text
View/download PDF

20. Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer

Author

Lorusso, Domenica, Mainenti, Sara, Pietragalla, Antonella, Fusco, E, Malaguti, Paola, Masciullo, Valeria, Scambia, Giovanni, Scambia, Giovanni (ORCID:0000-0003-2758-1063), Lorusso, Domenica, Mainenti, Sara, Pietragalla, Antonella, Fusco, E, Malaguti, Paola, Masciullo, Valeria, Scambia, Giovanni, and Scambia, Giovanni (ORCID:0000-0003-2758-1063)

Abstract

It was the aim of our study to evaluate the efficacy and safety of weekly topotecan in patients with advanced or recurrent cervical disease.

Published
2011

21. Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

Author

Fabi, Alessandra, primary, Merola, Roberta, additional, Ferretti, Gianluigi, additional, Di Benedetto, Anna, additional, Antoniani, Barbara, additional, Ercolani, Cristiana, additional, Nisticò, Cecilia, additional, Papaldo, Paola, additional, Ciccarese, Mariangela, additional, Sperduti, Isabella, additional, Vici, Patrizia, additional, Marino, Mirella, additional, Gori, Stefania, additional, Botti, Claudio, additional, Malaguti, Paola, additional, Cognetti, Francesco, additional, and Mottolese, Marcella, additional

Published
2013
Full Text
View/download PDF

24. A Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of 5-Fluorouracil Degradation Rate by Intact Peripheral Blood Mononuclear Cells

Author

Lostia, Alfonso M, primary, Lionetto, Luana, additional, Ialongo, Cristiano, additional, Gentile, Giovanna, additional, Viterbo, Antonella, additional, Malaguti, Paola, additional, Paris, Ida, additional, Marchetti, Luca, additional, Marchetti, Paolo, additional, Blasi, Antonio De, additional, and Simmaco, Maurizio, additional

Published
2009
Full Text
View/download PDF

25. An update on palonosetronhydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting

Author

Fabi, Alessandra and Malaguti, Paola

Abstract

Introduction:Nausea and vomiting are well recognized in different clinical situations, suggesting that no single mechanism is likely to be responsible for their production. Chemotherapy-induced nausea and vomiting (CINV) can have a negative impact on quality of life and this may lead to a refusal of curative therapy or to a decline in palliative benefits offered by cytotoxic treatment. Palonosetronis a new agent in the class of 5-HT3 receptor antagonists (5-HT3RAs), and differs from the other agents by its higher receptor-binding affinity and longer half-life. These pharmacological properties have resulted in improved antiemetic activity in clinical trials, particularly in the treatment of delayed CINV following moderate emetogenic chemotherapy (MEC).Area covered:A systematic review of the medical literature was completed to inform this update. MEDLINE, the Cochrane Collaboration Library and meeting materials from ASCO and MASCC were all searched.Expert opinion:Palonosetron was the only serotonin receptor antagonist approved for prevention of delayed CINV caused by MEC and its use was incorporated in guideline recommendations. To date, several treatment settings such as multiple day chemotherapy require further studies to improve emesis related to therapy.

Published
2013
Full Text
View/download PDF

27. The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.

Author

Malaguti P, Vari S, Cognetti F, and Fabi A

Subjects
Clinical Trials as Topic, Drug Resistance, Neoplasm genetics, Estrogens metabolism, Everolimus, Female, Humans, Molecular Targeted Therapy, Phosphatidylinositol 3-Kinases metabolism, Proto-Oncogene Proteins c-akt metabolism, Receptor, ErbB-2 metabolism, Sirolimus analogs & derivatives, Sirolimus therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Breast Neoplasms pathology, Neoplasms, Hormone-Dependent metabolism, Neoplasms, Hormone-Dependent pathology, Neoplasms, Hormone-Dependent therapy, TOR Serine-Threonine Kinases antagonists & inhibitors, TOR Serine-Threonine Kinases genetics, TOR Serine-Threonine Kinases metabolism
Abstract

Mammalian target of rapamycin (mTOR) is a crucial mediator of tumor progression and may be a promising target in a significant proportion of patients with breast cancer. More specifically, the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mTOR pathway plays a critical role in multiple cellular functions including metabolism, proliferation, growth and survival. This pathway is higly active in many types of cancer and is linked to resistance to many types of therapy. Direct blockade of the mTOR pathway is a new area in breast cancer therapy, with the potential to modulate growth factor- and estrogen-dependent and estrogen-independent pathways, which contribute to the pathogenesis and progression of tumors. Thus, inhibitors of mTOR are of interest as potential therapeutic agents for patients with breast cancer, everolimus and temsirolimus being the main representatives of this category. This review of the literature analyzes the available data emerging from trials and evaluates the efficacy and safety of mTOR inhibitors in all subtypes of breast cancer.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results